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Abstract: Phage therapy is an abandoned antimicrobial therapy that has been resumed in recent
years. In this study, we mutated a lysogenic phage from Acinetobacter baumannii into a lytic
phage (Ab105-2phi∆CI) that displayed antimicrobial activity against A. baumannii clinical strain
Ab177_GEIH-2000 (isolated in the GEIH-REIPI Spanish Multicenter A. baumannii Study II 2000/2010,
Umbrella Genbank Bioproject PRJNA422585, and for which meropenem and imipenem MICs
of respectively, 32 µg/mL, and 16 µg/mL were obtained). We observed an in vitro synergistic
antimicrobial effect (reduction of 4 log–7 log CFU/mL) between meropenem and the lytic phage in all
combinations analyzed (Ab105-2phi∆CI mutant at 0.1, 1 and 10 MOI and meropenem at 1/4 and 1/8
MIC). Moreover, bacterial growth was reduced by 8 log CFU/mL for the combination of imipenem
at 1/4 MIC plus lytic phage (Ab105-2phi∆CI mutant) and by 4 log CFU/mL for the combination of
imipenem at 1/8 MIC plus lytic phage (Ab105-2phi∆CI mutant) at both MOI 1 and 10. These results
were confirmed in an in vivo model (G. mellonella), and the combination of imipenem and mutant
Ab105-2phi∆CI was most effective (p < 0.05). This approach could help to reduce the emergence of
phage resistant bacteria and restore sensitivity to antibiotics used to combat multi-resistant strains of
Acinetobacter baumannii.
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1. Introduction
Multi-drug resistant (MDR) bacteria, such as A. baumannii are considered to be a major concern by
the World Health Organization (WHO), because of their ability to acquire antimicrobial resistance via
intrinsic characteristics and mechanisms (e.g., presence of the outer membrane) or via mechanisms
acquired by horizontal genetic transfer [1,2]. This situation has led to an urgent need to develop new
antimicrobial agents and to a renewed interest in phage therapy. Phage therapy was first developed in
the 1920s but was abandoned in the Western world after the discovery of antibiotics. However, the use
of phage therapy continued in Eastern countries, such as Poland and USSR, where bacteriophages
are used for the prophylaxis and treatment of infections, such as dysentery, ulcers, and methicillin
resistant Staphylococcus aureus (MRSA) infections [3,4].
Phage therapy is now considered a real option for treating MDR bacteria, and there are some
examples of its use in treating human patients [5]. Phages are bacterial viruses, and like other
viruses, they are obligate parasites that enter host cells through mechanisms that are based on receptor
recognition. Genetic material is then injected into the bacteria and use the bacterial machinery to
produce phage proteins [6,7]. Phages generally undergo a lytic (virulent) or lysogenic (temperate)
life cycle. Lytic phages infect, and rapidly lyse and kill host cells, releasing phage progeny into the
surrounding medium. Lysogenic phages infect the host cell and integrate their nucleic acid into
the host genome, or exist as plasmids in the host cells, remaining in a stable prophage state for
generations. Prophages can be “induced” to exit the cell as lytic phages under some conditions, such as
the presence of antibiotics [8,9]. The lysogenic/lytic cycle of temperate bacteriophages is controlled by
Cro, CI, and CII proteins; the Cro protein induces the lytic state and the CI repressor protein inhibits
the Cro protein, thereby inducing the lysogenic state [10].
Only lytic phages are used in phage therapy as lysogenic phages can transfer resistance genes or
virulence factors to the host [11].
The combined use of antibiotics and phages has been tested in several studies, demonstrating strong
control of the bacteria, and a reduction in the development of phage and/or antibiotic resistance [12,13].
Phages are good candidates for use in combination with antibiotics for various reasons, including
that they have a different mechanism of action from antibiotics; hold a narrow spectrum of activity,
which protects the normal microbiota; they can multiply at the infection site; they are abundant in
nature and can be easily isolated; and production costs are low [14–16].
In this study, we produced a mutant lytic phage from a lysogenic phage, that is incorporated in the
genome of a clinical strain of A. baumannii by deleting the CI repressor gene, and thus, preventing the
entry of the phage into the lysogenic cycle [10,17]. We then tested the antimicrobial activity of the
novel lytic phage, Ab105-2phi∆CI, in combination with carbapenem antibiotics (meropenem and
imipenem) against a carbapenem-resistant strain of A. baumannii. The combined therapy enhanced
the antimicrobial activity of both, the phage and the antibiotic; the bacterium became sensitive to the
antibiotics and the emergence rate of phage resistant bacteria was reduced.
2. Material and Methods
2.1. Bacterial Strains
In this study, we used 20 clinical strains isolated from Spanish hospitals during the GEIH-REIPI
Spanish Multicenter Acinetobacter baumannii Study II 2000–2010, GenBank Umbrella project
PRJNA422585 (https://www.ncbi.nlm.nih.gov/bioproject) (Table 1).
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Table 1. Bacterial strains used in this study. Phage host range determined by spot test and efficiency of
plating (EOP).
Strain ST Spot EOP Spanish Hospital Where the Strain Was Isolated
Ab105_GEIH-2010 2 +/− 1 Hospital Universitario Virgen del Rocío (Seville, Spain)
Ab192_GEIH-2000 2 +/− 0.22 Hospital Universitario Virgen del Rocío (Seville, Spain)
Ab404_GEIH-2010 80 + 0.0002 Hospital Dr. Molines (Valencia, Spain)
Ab166_GEIH-2000 2 +/− - Hospital Universitario Virgen del Rocío (Seville, Spain)
Ab177_GEIH-2000 2 + 1.55 Hospital Universitario Virgen del Rocío (Seville, Spain)
Ab13_GEIH-2010 79 - - Hospital Santiago de Compostela(Santiago de Compostela, Spain)
Ab09_GEIH-2010 297 - - Hospital Santiago de Compostela(Santiago de Compostela, Spain)
Ab160_GEIH-2000 2 - - Hospital Universitario Virgen del Rocío (Seville, Spain)
Ab155_GEIH-2000 2 - - Hospital Universitario Virgen del Rocío (Seville, Spain)
Ab05_GEIH-2010 186 - - Hospital A Coruña (A Coruña, Spain)
Ab22_GEIH-2010 52 - - Hospital Pontevedra (Pontevedra, Spain)
Ab421_GEIH-2010 2 - - Hospital Insular (Gran Canaria, Spain)
Ab77_GEIH-2000 2 - - Hospital Universitario Ramon y Cajal (Madrid, Spain)
Ab141_GEIH-2000 179 - - Complejo Hospitalario Toledo (Toledo, Spain)
Ab217_GEIH-2010 2 - - Hospital Reina Sofía (Cordoba, Spain)
Ab235_GEIH-2010 2 - - Hospital Marqués de Valdecilla (Santander, Spain
Ab37_GEIH-2010 2 - - Hospital Virgen del Rocío (Seville, Spain)
Ab222_GEIH-2000 181 - - Hospital Bellvitge (Barcelona)
Ab461_GEIH-2010 2 - - Hospital del Mar (Barcelona, Spain)
Ab173_GEIH-2010 88 - - Hospital San Agustín (Avilés, Spain)
ST: Sequence Type. Spot test: (+) clear spot; (+/−) turbid spot; (-) no spot.
2.2. Obtaining the Lytic Phage Mutant
The bacteriophage sequence Ab105-2phi (Genbank: KT5880759) detected in clinical strain
A. baumannii Ab105GEIH_2010 was analyzed and the CI gene identified as ORF 17. The CI gene was
deleted by double homologous recombination with the suicide vector pMo130TelR [18,19]. The primers
were first designed for the amplification of the flanking regions (1000 bp) of the CI gene. These regions
were amplified by PCR and ligated and cloned into the pMo130telR vector (Table 2). This construction
was transformed in Escherichia coli DH5α to produce large numbers of the plasmid with the gene
flanking regions. The plasmid was purified and transformed in the A. baumannii Ab105 clinical
strain by electroporation, and incubated for two hours at 37 ◦C without antibiotic, thereby producing
a recombinant wild type with the mutated gene integrated in its genome. Finally, the mutants were
selected in the presence of kanamycin (50 µg/mL). In order to isolate only those mutants with the CI
gene deletion in the chromosome, the plasmid loss was induced in the absence of kanamycin, and the
recombinant clones were selected in the presence of 15% sucrose. In order to isolate the mutant phage
Ab105-2phi∆CI from the bacterial clones by which the CI gene was deleted, a selected clone was
incubated in LB broth, which is supplemented with mitomycin (10 ug/mL) to induce release of the
phages. The supernatant was collected, treated with chloroform, and filtered (20 µm). The filtered
supernatant was used to infect the clone without the phage, and plaques were obtained by the agar
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overlay method [20]. A clear plaque was isolated by PCR and sequencing was conducted to confirm
the correct deletion of the CI gene.
Table 2. Primers used to delete the CI gene.
Primer Sequence Strain/Plasmid
UPCI [NotI]Fw GGGGCGGCCGCTGAAGAATTCATCACTTG Ab105_GEIH-2010
UPCI[BamHI]Rev GGGGGATCCCGTTACTTCTATCGGAAT Ab105_GEIH-2010
DWCI[BamHI]Fw GGGGGATCCATTAAGGTTTTAGGTGAT Ab105_GEIH-2010
DWCI[SphI]Rev GGGGCATGCTAAATCATCCAAATCGAC Ab105_GEIH-2010
CIFw ATGGACAAATTTATGGCTAC Ab105_GEIH-2010
CIRev TAACTTTTTCTAACACGCT Ab105_GEIH-2010
IntCIFw AAAGCGCTGCCAACTTTT Ab105_GEIH-2010
IntCIRev CAACAGATTCATCCTCAT Ab105_GEIH-2010
pMo130TelRFw ATTCATGACCGTGCTGAC pMo130TelR
pMo130TelRRev CTTGTCTGTAAGCGGATG pMo130TelR
Plasmid Description Origin
pMo130TelR Suicide plasmid, xylE+, sacB+, kmR, TelR [19]
Restriction enzyme sites are shown in italics.
A clone of strain Ab105GEIH_2010, induced with mitomycin, was isolated and excision of the
phage was confirmed by PCR of the CI gene and the flanking regions (1000 pb each region) of the gene.
2.3. Host Range and Efficiency of Plating Analysis
The host range of the lytic mutant phage Ab105-2phi∆CI was established by applying the spot
test [21] to the 20 clinical strains of A. baumannii under study. Efficiency of Plating (EOP) was established
as the ratio between the test strain titre and the host strain titre [22].
2.4. Transmission Electron Mmicroscopy (TEM) and Live-Cell Imaging
A broth culture of strain Ab177_GEIH-2000 was infected with the lytic mutant phage
Ab105-2phi∆CI. The lysates were centrifuged at 3400× g for 10 min and the supernatant was filtered
through a 0.22 µm filter (Merck Millipore, Ltd. Tullagreen, Carrigtwahill, Co Cork, Ireland). NaCl was
added to a final concentration of 0.5 M, and the suspensions were mixed thoroughly and left on ice
for 1 h. The suspensions were centrifuged at 3400× g for 40 min at 4 ◦C, and the supernatants were
transferred to sterile tubes. PEG 6000 (10% w/v) was added, dissolved, and incubated overnight at 4 ◦C.
Bacteriophages were then precipitated at 3400× g for 40 min at 4 ◦C and resuspended in SM buffer (0.1
M NaCl, 1 mM MgSO4, 0.2 M Tris-HCl, pH 7.5) [23]. The samples were negatively stained with 1%
aqueous uranyl acetate before examination by electron microscopy.
Live-cell imaging was carried out by time-lapse microscopy after initial adsorption of the mutant
lytic phage Ab105-2phi∆CI to the clinical strain Ab177_GEIH-2000 at 37 ◦C in agar slices, which were
placed directly between stainless steel O-rings. The use of extracellular DNA markers enabled the lysis
of more than 300 bacteria to be monitored in real time.
2.5. Adsorption Curve, One Step Growth Curve, and Infection Curve
An overnight culture of A. baumannii clinical strain Ab177_GEIH-2000 was diluted 1:100 in LB
broth, and incubated at 37 ◦C at 180 rpm, until an early logarithmic phase, i.e., at an optical density of
0.2 (OD 600nm). At this point the culture was infected with the lytic mutant phage Ab105-2phi∆CI at
Microorganisms 2019, 7, 556 5 of 14
a multiplicity of infection (MOI) of 0.1. The adsorption curve and the one step growth curve were
determined after growing the phage in LB, supplemented with CaCl2, as previously described [20,24].
In the one step growth curve, the latent period was defined as the interval between adsorption of
the phages to the bacterial cells and the release of phage progeny. The burst size of the phage was
determined as the ratio of the final number of free phage particles to the number of infected bacterial
cells during the latent period [22].
An early exponential culture of the strain Ab177_GEIH-2000 in LB, supplemented with CaCl2,
was infected with the lysogenic phage Ab105phi2 and the mutant lytic phage Ab105phi2∆CI at different
MOIs (0.1, 1 and 10), and the corresponding infection curves were constructed. The phage cultures
were maintained at room temperature during the adsorption period and then incubated at 37 ◦C and
180 rpm for 6 h. The optical density was measured at intervals of one hour during this period.
2.6. Frequency of Occurrence of Phage Resistant Bacteria
Phage resistant mutants were produced as previously described [25]. To determine the emergence
of phage resistant mutants, an overnight culture of strain Ab177_GEIH-2000 was diluted 1:100 in LB
and grown to an OD600nm of 0.6–0.7. An aliquot of 100 µL of the culture containing 108 colony forming
units (CFU)/mL was serially diluted, and each dilution mixed with 100 µL of 109 plaque forming units
(PFU)/mL, and plated by the agar overlay method [20]. The plates were incubated at 37 ◦C for 18h and
the number of CFUs was counted. The same procedure was used to produce phage resistant mutants
in the presence of the antibiotics doxycycline, meropenem, or imipenem, which were added to the
plates, each at 25% of the minimum inhibitory concentration (MIC). The frequency of occurrence of
phage resistant mutants and phage-antibiotic resistant mutants was calculated by dividing the number
of resistant bacteria by the total number of sensitive bacteria.
2.7. Antimicrobial Activity of the Mutant Lytic Phage Ab105-2phi∆CI in Biofilm
An overnight culture of the A. baumannii clinical strain Ab177_GEIH-2000 was diluted 1:100 and
used to inoculate 100 µL of LB in some wells of a 96 multi-well plate. The plate was maintained
at 37 ◦C in static conditions for 4 h. The medium was then discarded and the wells were washed
twice with PBS before 100 µL of fresh LB was added. After 24 h at 37 ◦C, the medium was again
discarded and the wells were washed with PBS, and filled with 90 µL of SM buffer, then 10 µL of phage
Ab105-2phi∆CI (107 PFU/mL) was added. SM buffer (100 µL) was added to control wells. The plates
were then incubated at 37 ◦C for 24 h. Finally, the supernatant was discarded and the wells were
washed with PBS. Half of the wells were used to quantify the CFUs and the other half were used to
quantify the biofilm. PBS (100 µL) was added to the wells used to quantify the CFUs and the plates
were agitated for 5 min and sonicated for another 5 min. The suspension was serially diluted and
plated on LB plates. For quantification of the biofilm, 100 µL of methanol was added to each well and
discarded after 10 min. Once the methanol had completely evaporated, 100 µL of crystal violet (0.1%)
was added and discarded after 15 min. Finally, the wells were washed with PBS before the addition of
150 µL of acetic acid (30%), and the absorbance was measured at OD 595 nm.
2.8. Antimicrobial Activity in Combination with Antibiotics
A bacterial killing assay was constructed to determine the synergy of phage Ab105-2phi∆CI
in combination with meropenem, imipenem and doxycycline at 1/8 and 1/4 of the respective MICs
(meropenem 32 µg/mL, imipenem 16 µg/mL and doxycycline 64 µg/mL). An overnight culture of the
tested strain was diluted at 1:100 in LB broth supplemented with 10uM CaCl2 and incubated at 37 ◦C
and 180 rpm until the culture reached an early exponential phase at 0.2 OD (600nm). At this point,
antibiotic and the Ab105-2phi∆CI phage were added to the culture. The flasks were maintained at
room temperature during the adsorption period before being incubated at 37 ◦C and 180 rpm for
24 h. Aliquots were removed after 6 h and 24 h and were serially diluted and plated in LB plates for
subsequent counting of CFU.
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2.9. Galleria mellonella Survival Assay
The Galleria mellonella model used was an adapted version of a previously developed model
also used to study bacteriophage therapy [26,27]. The procedure was as follows: twelve G. mellonella
larvae, acquired from TruLarvTM (Biosystems Technology, Exeter, Devon, UK), were each injected
in the left proleg with 10 µL of a suspension of A. baumannii Ab177_GEIH-2000, diluted in sterile
phosphate buffer saline (PBS) containing 1 × 105 CFU (± 0. 5 log). The injection was performed with
a Hamilton syringe (volume 100 µL) (Hamilton, Shanghai, China). One hour after infection, the larvae
were injected in the right proleg with 10 µL of the lytic mutant phage Ab105-2phi∆CI, at MOI 10,
in combination with meropenem at 1/4 MIC and imipenem at 14 MIC. The controls included 10 µL of
the lytic mutant phage Ab105-2phi∆CI at MOI 10, or meropenem at 1/4 MIC and imipenem at 1/4 MIC.
The injected larvae were placed in Petri dishes and incubated in darkness at 37 ◦C. The number of dead
larvae was recorded after 72 h. The larvae were considered dead when they showed no movement in
response to touch [26].
The survival curves for the in vivo G. mellonella infection model were constructed using GraphPad
Prism v.6 (San Diego, CA, USA), where the data were analyzed using the Log-Rank (Mantel-Cox,
City, State if USA, Country) test. The data were expressed as mean values, and the differences were
considered statistically significant at p < 0.05.
3. Results
3.1. Obtaining the Lytic Mutant of the Phage Ab105phi-2∆CI
After deleting the CI gene from the temperate phage Ab105-phi2, as previously reported in
Salmonella [17], we obtained a lytic mutant, designated Ab105-phi2∆CI, which produced characteristic
clear lytic plaques. This is in contrast with the turbid plaques produced by the temperate Ab105-phi2
phage (Figure 1A1). PCR of the DNA, isolated from the Ab105-2phi∆CI phage, confirmed the deletion
of the CI gene. PCRs were conducted with the CI genes and combinations of these primers with
those of the flanking regions, confirming that no amplification was obtained. PCRs with the primers
(UPCI[NotI]Fw/DWCI[SphI]Rev) of the flanking regions of the gene CI were also conducted, and the
expected region of 2000 pb was obtained (size without the CI gene). Finally, this amplicon was
sequenced and the CI gene deletion was confirmed. Excision of the phage was also confirmed in
a clone induced with mitomycin, as no positive PCR were obtained with the CI primers or with the
flanking region primers.
Infection curves for the temperate phage Ab105-2phi and the lytic mutant phage Ab105-2phi∆CI
were constructed and compared, showing that the lytic mutant killed the culture at all MOI levels tested,
as reflected by a large decrease in the optical density. Although, a reduction in growth was observed
when the culture was infected with the lysogenic phage Ab105-2phi, the decrease was less than with
the lytic mutant. In both cases, the reduction in growth was first observed at MOI 10, but regrowth
was also first observed at this MOI, probably due to the emergence of resistance (Figure 1B).
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Statistically significant differences (p < 0.05) were determined by t-Student test (GraphPad Prism v.6). 
3.5. Determination of the Emergence Rate of Phage Resistant Mutants 
Strain Ab177_GEIH-2000 was resistant to meropenem, imipenem and doxycycline (MICs: 
Meropenem 32 μg/mL, imipenem 16 μg/mL, and doxycycline 64 μg/mL). In all cases the 
Figure 1. Graphical representation of the Ab105-2phi∆CI phage. The ORF and direction of transcription
are indicated by arrows. (A1) The protein functions are indicated in different colours, and the GC content
and GC skew are shown as pink and green circles respectively. (A2) TEM image of the mutant lytic
phage Ab105-phi2∆CI and mutant lytic phage Ab105-phi2∆CI attached to the cell surface. (B1) Infection
curves for the lysogenic phage Ab105-2phi and (B2) the mutant lytic phage Ab105-2phi∆CI. (C) One step
growth curve of the mutant lytic phage Ab105-phi2∆CI (L: Latent period; B: burst size). Mutant lytic
phage Ab105-phi2∆CI antibiofilm activity on the biofilm produced by the clinical strain of A. baumannii
Ab177_GEIH-2000. (D1) Reduction in the biofilm and reduction in the number of CFUs present in the
biofilm after treatment with the mutant lytic phage Ab105-phi2∆CI (D2). Figures B, C and D show the
mean values +/− SD from three independent assays. Statistically significant differences (p < 0.05) were
determined by t-Student test (GraphPad Prism v.6).
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3.2. Morphology and Host Range of the Lytic Mutant Phage Ab105-phi2∆CI
The lytic mutant Ab105-2phi∆CI was isolated and the virion morphology was observed by
TEM, revealing that this phage has the typical structure of the Siphoviridae as the wild type phage
Ab105-phi2 [28]. All plaques were transparent and about 1mm in diameter (Figure 1A2).
The lytic spectrum of activity of the mutant phage Ab105-2phi∆CI covered 25% of the clinical
strains of A. baumannii tested. The strain Ab177_GEIH-2000 yielded the highest EOP (1.55) (Table 1).
This strain was thus selected for further assays.
3.3. Adsorption and One Step Growth Curve
Both, the adsorption and the one step growth curve were established using host strain
Ab177_GEIH-2000, as the EOP of this strain was the most appropriate and also because this strain
does not have complete prophages, as previously determined [28]. The adsorption time (12 min) was
determined in order to establish the one step growth curve, which revealed a latent period of 30 min
and a burst size of approximately 32 ± 2 PFU per infected cell (Figure 1C).
3.4. Antimicrobial Activity of the Mutant Lytic Phage Ab105-2phi∆CI on Biofilm
Biofilm was produced with the clinical strain of A. baumannii Ab177_GEIH-2000 susceptible to the
mutant lytic phage Ab105-phi2∆CI. The treatment of the biofilm with 107 PFU of this lytic mutant
phage caused a statistically significant reduction in the biofilm biomass. The antimicrobial activity
against the biofilm forming bacteria was confirmed by a decrease in the CFU, quantified in the presence
of the mutant lytic phage (Figure 1D).
Finally, the lytic activity of the mutant phage can be observed in Video 1 (Supplementary Materials).
3.5. Determination of the Emergence Rate of Phage Resistant Mutants
Strain Ab177_GEIH-2000 was resistant to meropenem, imipenem and doxycycline (MICs:
Meropenem 32 µg/mL, imipenem 16 µg/mL, and doxycycline 64 µg/mL). In all cases the combination
of the phage and antibiotic reduced the rate of emergence of phage-resistant mutants, relative to the
rate of resistant mutants in the presence of the phage alone (Table 3).
Table 3. Frequency of phage resistant mutants. Phage resistant mutant frequency in the presence of the
combination of doxycycline, meropenem and imipenem at 14 MIC in combination with lytic mutant
phage Ab105-2phi∆CI (MOI 10) was calculated.
Sample Frequency of Phage Resistant Mutants
Ab105-2phi∆CI 1.70 × 10−6
Ab105-2phi∆CI + Doxycycline 1.31 × 10−7
Ab105-2phi∆CI + Meropenem 2.10 × 10−7
Ab105-2phi∆CI + Imipenem 1.90 × 10−7
3.6. Effect of the Combination of Phage and Antibiotic on the Bacterial Killing Assays
Bacterial killing assays were constructed for A. baumannii clinical strain Ab177_GEIH-2000 in the
presence of a combination of the lytic mutant phage Ab105-2phi∆CI at different MOIs (0.1, 1, and 10)
and three antibiotics (at 1/4 and 1/8 MIC) to which Ab177_GEIH-2000 is resistant: Meropenem,
imipenem, and doxycycline (Figure 2).
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Figure 2. Bacterial killing assays for . ba a ii cli ical strai 177_ I -2000 eter i e si
the utant lytic phage b105-2phi∆CI at OI 1 and OI10 in combination with meropenem at (A1)
1/8 I and ( 2) 1/4 MIC;(B1) imipenem at 1/8 MIC and (B2)1/4 MIC, and (C1) doxycycline at 1/8 MIC
and (C2)1/4 MIC. Values shown in the graphs are the means +/− SD from three independent assays.
A reduction in the number of CFU was observed with the phage at both MOI 1 (4 log) and MOI
10 (1 log) after 6 h, but no differences from the control were observed after 24 h. The reduction was
even greater when the phage was combined with meropenem or imipenem (both carbapenems).
For meropenem plus phage, a synergistic effect was observed after 6 h for all combinations
(from 4 log to 7 log CFU/mL). The growth of the A. baumanni strain was similar to control levels
after 24 h for all concentrations of meropenem plus phage at MOI 1. The synergistic effect was
only maintained with the combination of meropenem at 1/4 MIC and phage Ab105-2phi∆CI at
MOI10, yielding a difference in bacterial growth of 6 log CFU/mL, relative to that corresponding to the
meropenem control (Figure 2A1,2A2).
As with meropenem, the combination of different concentrations of imipenem and the lytic mutant
phage had a synergistic effect after 6 h in all cases, with a reduction in bacterial growth of 8 log CFU/mL
for the combination of imipenem at 1/4 MIC, plus phage, and 4 log CFU/mL for the combination of
imipenem at 1/8 MIC plus phage. The synergistic effect was maintained for 24 h in the combinations of
imipenen at 1/4 MIC, with phage at MOI1 and MOI10, but not in the combinations of imipenem at
1/8 MIC and both phage concentrations (Figure 2B1,2B2).
No synergistic effects were observed with doxycycline, and the combination had no more effect
than the phage alone at MOI 1. However, when the combinations included the phage at MOI 10,
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a slight decrease in the CFU count was observed (less than 1 log CFU/mL), independently of the
antibiotic concentration (Figure 2C1,2C2).
The curves obtained for the lytic mutant phage controls showed that Ab177_GEIH-2000 grew at
control rates after 24h, due to the acquisition of phage resistance. However, the growth was higher
at MOI 10, than at MOI 1 after 6 h, probably because resistance emerges faster at this MOI than at
lower MOI.
3.7. Galleria mellonella Survival Assays in the Presence of Meropenem and Imipenem in Combination with the
Lytic Mutant Phage Ab105-phi2∆CI
The combinations of antibiotic and the phage Ab105-2phi∆CI, that resulted in the reduction of the
CFU of Ab177_GEIH-2000 at 24h in vitro were assayed in a G. mellonella (wax moth) larvae survival
model (Figure 3). When the infected larvae were treated with imipenem and mutant lytic phage
Ab105-2phi∆CI, the survival rate was found to be statistically significantly higher than the larvae
treated with the antibiotic or the phage alone and of untreated larvae (p < 0.05). Similar results were
obtained for meropenem but in this case. Although, larval survival was higher after the combinatory
treatment than after phage only or no treatment, the difference relative to meropenem alone was not
statistically significant (p = 0.2183). This was probably due to the higher MIC of meropenem than
of imipenem (32 µg/mL versus 16 µg/mL) for the Ab177_GEIH-2000 strain, indicating the need to
administer greater amounts of mutant lytic phage Ab105-2phi∆CI.Microorganisms 2019, 7, x 10 of 13 
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4. Discus ion
Lytic phages are widel e therapy, but temperate or lysogenic phages have not
generally been si r suitable for the purpose, becaus they can enhance host competence
and survival. However, temperate phages are present in almost half of bacteria that have been
sequenced. Phages that are specific to pathogens causing infections can be easily identified. In addition,
the problems caused by horizontal genetic transfer can now be avoided due to next generation
sequencing, which enables phages to be selected, that do not pose a risk of transferring undesirable
genes, such as endotoxins [15]. Temperate phages can also be easily engineered in their lysogenic state
for use in phage therapy, by different means: By modifying the genes of interest as phage receptors
to extend the host range; by inhibiting the lytic ability of phages without the release of endotoxins;
modifying genes to enhance the killing effect of bacteriophages; increasing the life time of phages in the
circulatory system of mammalians, and; transforming lysogenic phages into lytic phages [17,29–33].
In this study, we selected a temperate phage, Ab105-2phi, which did not have any toxic or
virulence genes in its genome (Figure 1A1). This phage was selected with the objective of converting
it into a lytic phage with potential use in phage therapy. The technique was previously described
in Salmonella enterica bacteriophage SPN9CC and in the mycobacteriophage BPs33∆ T _HRM10,
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recently used in a phage cocktail to treat a patient with a disseminated drug-resistant Mycobacterium
abscessus [17,34]. The technique is based on the deletion of the CI repressor gene, which encodes the CI
protein and binds to two operators, thereby repressing the Cro gene required for lytic development.
Deleting the CI gene thus maintains the phage in a lysogenic state [10,17].
Conversion of the lysogenic into a lytic phage was confirmed, first by PCR and sequencing.
Then, by the presence of clear plaques and by the infection curves for both phages: Lysogenic
Ab105-phi2 and the lytic mutant Ab105-phi2∆CI. The differences in optical density in both cases
confirmed the production of a lytic mutant, and the emergence of phage resistant mutants for both
phages. At MOI 10, the inhibition of growth was greater and occurred earlier than at other MOI, but
resistant bacteria emerged earlier than at lower MOI, as also observed by other authors [35]. In addition,
this effect was observed in the bacterial killing assays, where the growth at 6 h was greater at MOI10
than at MOI1. The mutant lytic phage also presented a latent period of 30 min, and a moderate burst
size of 32 ± 2 PFU per cell was obtained with the mutant lytic phage, values in the range of those
obtained in several studies for different lytic phages, including phages from A. baumannii [5,36–39].
The burst size is inversely related to the risk of emergence of phage resistant bacteria [40], which
is one of the main objectives of phage therapy research, commonly addressed by the use of phage
cocktails [41].
Although the antimicrobial activity of this mutant lytic phage was established by its ability to
reduce the absorbance in a bacterial culture and also to reduce the biofilm biomass, any reduction in the
development of phage resistance would increase its potential use as a therapeutic phage. In this case,
the strategy we combined the phage with antibiotics [13] to enhance the potential of the Ab105-2phi∆CI
phage as a therapeutic phage, and observed an almost 1 log reduction in the emergence of phage
resistant mutants in the presence of the antibiotics assayed. The synergistic effect (almost 2 log decrease
between the combined therapy and the compounds alone) resulted from the combination of the lytic
mutant phage Ab105-2phi∆CI, and meropenem or imipenem enhanced the bactericidal effect of both the
antibiotic and the phage. A strong antimicrobial effect was obtained by combining the phage at a high
MOI and the antibiotic at concentrations much lower than the MIC, thereby restoring the sensitivity
of the strain to imipenem and meropenem. As the host strain does not possess beta-lactamases,
the resistance is probably due to the action of a Resistance-Nodulation-Division (RND) efflux pump,
containing proteins that can act as phage receptor proteins. Therefore, the phage blocks the efflux
pump and the antibiotic sensitivity of the strain would thus be increased [42]. The activity of the efflux
pump explains the differences between antibiotics, as the efflux pumps that expulse carbapenems can
act on doxycycline, when present at low levels [43].
The increase in the antimicrobial activity when the carbapenem antibiotics and the mutant lytic
phage were used together was also confirmed in the survival assays with G. mellonella, as survival was
higher in larvae that received the combined treatments. However, when the combination included
meropenem (MIC, 32 µg/mL), survival was not statistically significantly higher, indicating that
administration of a larger number of mutant lytic phage Ab105-2phi∆CI would be necessary (in vivo).
In conclusion, this is the first in vitro and in vivo study by which a mutant lytic phage has been
used in combination with carbapenem antibiotics (imipenem and meropenem). This reduces the
emergence of resistance to the phages and restores the sensitivity to antibiotics, thereby increasing
the therapeutic potential of the phage. The conversion of temperate phages (with a known genomic
profile) into lytic phages may provide a new source of phages for use in phage therapy.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2076-2607/7/11/556/s1.
Video 1. Initial adsorption of phages to bacteria at 37 ◦C in agar slices placed directly between stainless steel
O-rings for live-cell imaging. Use of extracellular DNA markers enabled lysis of more than 300 bacteria to be
followed in real time.
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